406 related articles for article (PubMed ID: 23444197)
21. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
22. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
[TBL] [Abstract][Full Text] [Related]
23. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
24. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
25. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
26. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
Caudal D; Alvarsson A; Björklund A; Svenningsson P
Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
[TBL] [Abstract][Full Text] [Related]
27. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.
Gleave JA; Arathoon LR; Trinh D; Lizal KE; Giguère N; Barber JHM; Najarali Z; Khan MH; Thiele SL; Semmen MS; Koprich JB; Brotchie JM; Eubanks JH; Trudeau LE; Nash JE
Neurobiol Dis; 2017 Oct; 106():133-146. PubMed ID: 28673739
[TBL] [Abstract][Full Text] [Related]
28. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
29. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
30. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
31. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans.
Kuwahara T; Koyama A; Gengyo-Ando K; Masuda M; Kowa H; Tsunoda M; Mitani S; Iwatsubo T
J Biol Chem; 2006 Jan; 281(1):334-40. PubMed ID: 16260788
[TBL] [Abstract][Full Text] [Related]
32. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
33. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Junn E; Mouradian MM
Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
35. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.
Febbraro F; Sahin G; Farran A; Soares S; Jensen PH; Kirik D; Romero-Ramos M
Neurobiol Dis; 2013 Aug; 56():47-58. PubMed ID: 23567651
[TBL] [Abstract][Full Text] [Related]
36. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.
Taylor TN; Potgieter D; Anwar S; Senior SL; Janezic S; Threlfell S; Ryan B; Parkkinen L; Deltheil T; Cioroch M; Livieratos A; Oliver PL; Jennings KA; Davies KE; Ansorge O; Bannerman DM; Cragg SJ; Wade-Martins R
Neurobiol Dis; 2014 Feb; 62():193-207. PubMed ID: 24121116
[TBL] [Abstract][Full Text] [Related]
37. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
38. Motor deficits and beta oscillations are dissociable in an alpha-synuclein model of Parkinson's disease.
Brys I; Nunes J; Fuentes R
Eur J Neurosci; 2017 Aug; 46(3):1906-1917. PubMed ID: 28370471
[TBL] [Abstract][Full Text] [Related]
39. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
[TBL] [Abstract][Full Text] [Related]
40. Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons.
Taschenberger G; Garrido M; Tereshchenko Y; Bähr M; Zweckstetter M; Kügler S
Acta Neuropathol; 2012 May; 123(5):671-83. PubMed ID: 22167382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
